公开(公告)号：US07326421B2

公开(公告)日：2008-02-05

申请号：US10690972

申请日：2003-10-21

申请人： John H. Brekke ,  John H. Gubbe

发明人： John H. Brekke ,  John H. Gubbe

IPC分类号： A61F2/00 ,  A61K31/33 ,  A61K31/335 ,  A61K31/28

CPC分类号： A61K33/24 ,  A61K31/00 ,  A61K31/337 ,  A61K31/728 ,  A61K45/06 ,  A61L27/20 ,  A61L27/54 ,  A61L31/042 ,  A61L31/16 ,  A61L2300/224 ,  A61L2300/416 ,  A61L2300/602 ,  A61K2300/00 ,  C08L5/08

摘要： An implantable delivery system includes a macrostructure formed of bioresorbable material selected from a group of alphahydroxy acids and defined to include an internal architecture of intercommunicating void spaces. A first cytotoxic agent in the preferred form of cisplatin is joined to the macrostructure during formation. A microstructure in the preferred form of a blend of high molecular weight hyaluronic acid conjugated with a second cytotoxic agent in the preferred form of paclitaxel and of pure high molecular weight hyaluronic acid is invested in the void spaces. Thus, when implanted, the paclitaxel and cisplatin are released sequentially, each initially at high level concentrations followed by lower release. Radiotherapy can be begun after the release of the paclitaxel has been completed but while the cisplatin is being released.

摘要翻译： 可植入递送系统包括由生物可再吸收材料形成的宏观结构，所述生物可吸收材料选自α-羟基酸，并且被定义为包括相互通信的空隙空间的内部结构。 优选形式的顺铂的第一种细胞毒性剂在形成过程中与宏观结构相结合。 在优选形式的紫杉醇和纯高分子量透明质酸中与第二细胞毒剂偶联的高分子量透明质酸的混合物的优选形式的微结构被投入到空隙空间中。 因此，当植入时，依次释放紫杉醇和顺铂，各自最初以高浓度浓度释放。 在紫杉醇释放已经完成但顺铂释放之后，放射治疗可以开始。

公开(公告)号：US08314084B2

公开(公告)日：2012-11-20

申请号：US13117209

申请日：2011-05-27

申请人： John H. Brekke ,  John H. Gubbe

发明人： John H. Brekke ,  John H. Gubbe

IPC分类号： A61K31/33 ,  A61K31/335 ,  A61K31/28 ,  A61F2/00

CPC分类号： A61K33/24 ,  A61K31/00 ,  A61K31/337 ,  A61K31/728 ,  A61K45/06 ,  A61L27/20 ,  A61L27/54 ,  A61L31/042 ,  A61L31/16 ,  A61L2300/224 ,  A61L2300/416 ,  A61L2300/602 ,  A61K2300/00 ,  C08L5/08

摘要： An implantable delivery system includes a macrostructure formed of bioresorbable material selected from a group of alphahydroxy acids and defined to include an internal architecture of intercommunicating void spaces. A first cytotoxic agent in the preferred form of cisplatin is joined to the macrostructure during formation. A microstructure in the preferred form of a blend of high molecular weight hyaluronic acid conjugated with a second cytotoxic agent in the preferred form of paclitaxel and of pure high molecular weight hyaluronic acid is invested in the void spaces. Thus, when implanted, the paclitaxel and cisplatin are released sequentially, each initially at high level concentrations followed by lower release. Radiotherapy can be begun after the release of the paclitaxel has been completed but while the cisplatin is being released.

摘要翻译： 可植入递送系统包括由生物可再吸收材料形成的宏观结构，所述生物可吸收材料选自α-羟基酸，并且被定义为包括相互通信的空隙空间的内部结构。 优选形式的顺铂的第一种细胞毒性剂在形成过程中与宏观结构相结合。 在优选形式的紫杉醇和纯高分子量透明质酸中与第二细胞毒剂偶联的高分子量透明质酸的混合物的优选形式的微结构被投入到空隙空间中。 因此，当植入时，依次释放紫杉醇和顺铂，各自最初以高浓度浓度释放。 在紫杉醇释放已经完成但顺铂释放之后，放射治疗可以开始。

公开(公告)号：US20080124375A1

公开(公告)日：2008-05-29

申请号：US12024196

申请日：2008-02-01

申请人： John H. Brekke ,  John H. Gubbe

发明人： John H. Brekke ,  John H. Gubbe

IPC分类号： A61F2/00 ,  A61K31/337 ,  A61K33/24 ,  A61P35/00 ,  A61K31/728

CPC分类号： A61K33/24 ,  A61K31/00 ,  A61K31/337 ,  A61K31/728 ,  A61K45/06 ,  A61L27/20 ,  A61L27/54 ,  A61L31/042 ,  A61L31/16 ,  A61L2300/224 ,  A61L2300/416 ,  A61L2300/602 ,  A61K2300/00 ,  C08L5/08

摘要： An implantable delivery system includes a macrostructure formed of bioresorbable material selected from a group of alphahydroxy acids and defined to include an internal architecture of intercommunicating void spaces. A first cytotoxic agent in the preferred form of cisplatin is joined to the macrostructure during formation. A microstructure in the preferred form of a blend of high molecular weight hyaluronic acid conjugated with a second cytotoxic agent in the preferred form of paclitaxel and of pure high molecular weight hyaluronic acid is invested in the void spaces. Thus, when implanted, the paclitaxel and cisplatin are released sequentially, each initially at high level concentrations followed by lower release. Radiotherapy can be begun after the release of the paclitaxel has been completed but while the cisplatin is being released.

摘要翻译： 可植入递送系统包括由生物可再吸收材料形成的宏观结构，所述生物可吸收材料选自α-羟基酸，并且被定义为包括相互通信的空隙空间的内部结构。 优选形式的顺铂的第一种细胞毒性剂在形成过程中与宏观结构相结合。 在优选形式的紫杉醇和纯高分子量透明质酸中与第二细胞毒剂偶联的高分子量透明质酸的混合物的优选形式的微结构被投入到空隙空间中。 因此，当植入时，依次释放紫杉醇和顺铂，各自最初以高浓度浓度释放。 在紫杉醇释放已经完成但顺铂释放之后，放射治疗可以开始。

公开(公告)号：US07951394B2

公开(公告)日：2011-05-31

申请号：US12024196

申请日：2008-02-01

申请人： John H. Brekke ,  John H. Gubbe

发明人： John H. Brekke ,  John H. Gubbe

IPC分类号： A61F2/00 ,  A61K31/33 ,  A61K31/335 ,  A61K31/28

CPC分类号： A61K33/24 ,  A61K31/00 ,  A61K31/337 ,  A61K31/728 ,  A61K45/06 ,  A61L27/20 ,  A61L27/54 ,  A61L31/042 ,  A61L31/16 ,  A61L2300/224 ,  A61L2300/416 ,  A61L2300/602 ,  A61K2300/00 ,  C08L5/08

摘要： An implantable delivery system includes a macrostructure formed of bioresorbable material selected from a group of alphahydroxy acids and defined to include an internal architecture of intercommunicating void spaces. A first cytotoxic agent in the preferred form of cisplatin is joined to the macrostructure during formation. A microstructure in the preferred form of a blend of high molecular weight hyaluronic acid conjugated with a second cytotoxic agent in the preferred form of paclitaxel and of pure high molecular weight hyaluronic acid is invested in the void spaces. Thus, when implanted, the paclitaxel and cisplatin are released sequentially, each initially at high level concentrations followed by lower release. Radiotherapy can be begun after the release of the paclitaxel has been completed but while the cisplatin is being released.

摘要翻译： 可植入递送系统包括由生物可再吸收材料形成的宏观结构，所述生物可吸收材料选自α-羟基酸，并且被定义为包括相互通信的空隙空间的内部结构。 优选形式的顺铂的第一种细胞毒性剂在形成过程中与宏观结构相结合。 在优选形式的紫杉醇和纯高分子量透明质酸中与第二细胞毒剂偶联的高分子量透明质酸的混合物的优选形式的微结构被投入到空隙空间中。 因此，当植入时，依次释放紫杉醇和顺铂，各自最初以高浓度浓度释放。 在紫杉醇释放已经完成但顺铂释放之后，放射治疗可以开始。

公开(公告)号：US20110237858A1

公开(公告)日：2011-09-29

申请号：US13117209

申请日：2011-05-27

申请人： John H. Brekke ,  John H. Gubbe

发明人： John H. Brekke ,  John H. Gubbe

IPC分类号： A61N5/00 ,  A61M5/00

CPC分类号： A61K33/24 ,  A61K31/00 ,  A61K31/337 ,  A61K31/728 ,  A61K45/06 ,  A61L27/20 ,  A61L27/54 ,  A61L31/042 ,  A61L31/16 ,  A61L2300/224 ,  A61L2300/416 ,  A61L2300/602 ,  A61K2300/00 ,  C08L5/08

摘要： An implantable delivery system includes a macrostructure formed of bioresorbable material selected from a group of alphahydroxy acids and defined to include an internal architecture of intercommunicating void spaces. A first cytotoxic agent in the preferred form of cisplatin is joined to the macrostructure during formation. A microstructure in the preferred form of a blend of high molecular weight hyaluronic acid conjugated with a second cytotoxic agent in the preferred form of paclitaxel and of pure high molecular weight hyaluronic acid is invested in the void spaces. Thus, when implanted, the paclitaxel and cisplatin are released sequentially, each initially at high level concentrations followed by lower release. Radiotherapy can be begun after the release of the paclitaxel has been completed but while the cisplatin is being released.

摘要翻译： 可植入递送系统包括由生物可再吸收材料形成的宏观结构，所述生物可吸收材料选自α-羟基酸，并且被定义为包括相互通信的空隙空间的内部结构。 优选形式的顺铂的第一种细胞毒性剂在形成过程中与宏观结构相结合。 在优选形式的紫杉醇和纯高分子量透明质酸中与第二细胞毒剂偶联的高分子量透明质酸的混合物的优选形式的微结构被投入到空隙空间中。 因此，当植入时，依次释放紫杉醇和顺铂，各自最初以高浓度浓度释放。 在紫杉醇释放已经完成但顺铂释放之后，放射治疗可以开始。